Author: Julander, Justin G.; Demarest, James F.; Taylor, Ray; Gowen, Brian B.; Walling, Dennis M.; Mathis, Amanda; Babu, Y.S.
Title: An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral Cord-id: 1cn1fsxw Document date: 2021_9_20
ID: 1cn1fsxw
Snippet: Galidesivir (BCX4430) is an adenosine nucleoside analog that is broadly active in cell culture against several RNA viruses of various families. This activity has also been shown in animal models of viral disease associated with Ebola, Marburg, yellow fever, Zika, and Rift Valley fever viruses. In many cases, the compound is more efficacious in animal models than cell culture activity would predict. Based on favorable data from in vivo animal studies, galidesivir has recently undergone evaluation
Document: Galidesivir (BCX4430) is an adenosine nucleoside analog that is broadly active in cell culture against several RNA viruses of various families. This activity has also been shown in animal models of viral disease associated with Ebola, Marburg, yellow fever, Zika, and Rift Valley fever viruses. In many cases, the compound is more efficacious in animal models than cell culture activity would predict. Based on favorable data from in vivo animal studies, galidesivir has recently undergone evaluation in several phase I clinical trials, including against severe acute respiratory syndrome coronavirus 2, and as a medical countermeasure for the treatment of Marburg virus disease.
Search related documents:
Co phrase search for related documents- active site and acute viral disease: 1, 2, 3, 4
- active site and additional study: 1, 2
- active site and adenosine triphosphate: 1, 2, 3, 4
- active site and administration evaluate: 1
- active site and loading dose: 1
- active triphosphate form and acute respiratory syndrome: 1, 2, 3, 4, 5
- active triphosphate form and adenosine triphosphate: 1, 2, 3, 4, 5
- active triphosphate form and loading dose: 1
- activity demonstrate and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- activity demonstrate and loading dose: 1
- acute respiratory syndrome and additional study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and additional study ongoing: 1
- acute respiratory syndrome and adenosine triphosphate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute respiratory syndrome and administration evaluate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute respiratory syndrome and loading dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- additional study and loading dose: 1, 2
Co phrase search for related documents, hyperlinks ordered by date